Recent re-evaluations of the Women’s Health Initiative (WHI) findings have reshaped our understanding of menopause hormone therapy (MHT) and its implications for women’s health. Initially, the WHI reported increased risks of heart disease, stroke, and dementia associated with MHT, leading to a significant decline in its use. However, new insights suggest that MHT can be beneficial for women who start treatment around menopause, particularly concerning brain health.

This shift in perspective is crucial for the longevity and healthspan fields, as it highlights the importance of timing and hormone type in MHT administration. Research indicates that starting MHT during the menopause transition may support cognitive function, while delayed initiation could be linked to increased dementia risk. Additionally, the variety of MHT formulations and delivery methods can significantly influence health outcomes, emphasizing the need for personalized approaches in clinical practice.

For professionals in aging biology and healthspan research, the evolving narrative around MHT underscores the importance of tailored treatment strategies. Understanding the nuances of MHT can enhance patient care and potentially improve long-term cognitive health. I encourage you to delve into the full article for a comprehensive overview of these critical developments.

Source: superagingnews.com